PTPN11 and neoplasm: Analysis showed that high SHP2 mRNA expression of LAUD patients suffered poor overall survival (OS) (71.27 months vs. 112.67 months, p = 0.00062) and progression free survival (PFS) (21.3 months vs. 37 months, p = 0.00019) compared to patients expressing low levels of SHP2 mRNA, suggesting that SHP2 might be involved in the tumor progression of LUAD (Fig. 1A).